Servier will acquire the muscular dystrophy business of Edgewise Therapeutics for up to $2.65 billion, including an upfront payment of $1.55 billion and up to $1.1 billion in regulatory and commercial milestone payments. The transaction has been approved by both companies’ respective governance bodies and is expected to close in the third quarter of 2026, subject to regulatory clearance and customary closing conditions.
The sale includes the muscular dystrophy business of Edgewise Therapeutics, a biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. The transaction includes Edgewise’s associated capabilities as well as sevasemten, an investigational orally administered fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with rare muscular dystrophy.
Servier is a commercial-stage biotechnology company that specializes in medication for cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancers and diabetes. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries.
The transaction strengthens Servier’s presence in rare diseases and neuromuscular disorders. Lazard is serving as exclusive financial advisor to Servier, and McDermott Will & Schulte LLP is serving as legal counsel.
According to data captured in the LevinPro HC database, this represents the 62nd Biotechnology transaction of the year. There were 137 Biotechnology acquisitions recorded in 2025, and 139 announced in 2024.
